Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide ‐1 receptor agonists among people with diabetes: A propensity‐score matching study
Authors' conclusion
Our analysis demonstrates the potential advantages of SGLT2 inhibitors over GLP-1RAs in terms of kidney outcomes in individuals with diabetes.
Study context
- Population
- Individuals with diabetes newly initiating SGLT2 inhibitors or GLP-1RAs, JMDC claims database; median age 52 years, 80.6% menmatched
- Participants
- 2,549 individuals
- Exposure
- SGLT2 inhibitors vs GLP-1RAs
- SGLT2 inhibitorn = 2,039
- GLP-1RAn = 510reference
- Outcome
- Change in eGFR, estimated using a linear mixed-effects model
Methodological detailspropensity-score matched (1:4), claims database (JMDC), new-user design
- Propensity-score matched (1:4)
- Claims database (JMDC)
- New-user design
Main finding
As reported in the abstract
eGFR change
SGLT2 inhibitor
−1.41
95% CI −1.63–-1.19 · mL/min/1.73 m²
GLP-1RA
−2.62
95% CI −3.15–-2.10 · mL/min/1.73 m²
Observational data: associations, not effects.
Original publication
Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide ‐1 receptor agonists among people with diabetes: A propensity‐score matching study. Diabetes Obes Metab. Published 26 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →